Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

TXMD - TherapeuticsMD, Inc.


IEX Last Trade
1.095
-0.065   -5.936%

Share volume: 0
Last Updated: Thu 26 Dec 2024 09:17:13 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) : 0.90%

PREVIOUS CLOSE
CHG
CHG%

$1.16
-0.07
-5.60%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
23%
Profitability 23%
Dept financing 24%
Liquidity 75%
Performance 10%
Company vs Stock growth
vs
Performance
5 Days
1.38%
1 Month
-20.71%
3 Months
-32.72%
6 Months
-35.46%
1 Year
-54.87%
2 Year
-78.81%
Key data
Stock price
$1.10
P/E Ratio 
-3.57
DAY RANGE
$1.11 - $1.73
EPS 
-$0.54
52 WEEK RANGE
$1.14 - $2.75
52 WEEK CHANGE
-$52.96
MARKET CAP 
21.739 M
YIELD 
N/A
SHARES OUTSTANDING 
11.532 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
1.03
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$31,918
AVERAGE 30 VOLUME 
$20,254
Company detail
CEO: Mark A. Glickman
Region: US
Website: therapeuticsmd.com
Employees: 420
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services

TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone. It also manufactures and distributes branded and generic prescription prenatal vitamins.

Recent news